Atreca (NASDAQ:BCEL) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright reiterated their buy rating on shares of Atreca (NASDAQ:BCEL) in a report published on Wednesday morning, TipRanks reports. HC Wainwright currently has a $30.00 target price on the stock.

Several other equities analysts have also issued reports on BCEL. Robert W. Baird initiated coverage on Atreca in a research note on Wednesday, April 15th. They issued an outperform rating and a $30.00 target price on the stock. ValuEngine lowered shares of Atreca from a buy rating to a hold rating in a research note on Thursday, July 2nd. BidaskClub upgraded shares of Atreca from a hold rating to a buy rating in a research note on Thursday, June 25th. Zacks Investment Research raised Atreca from a hold rating to a strong-buy rating and set a $21.00 price target on the stock in a research report on Tuesday, May 19th. Finally, Wedbush initiated coverage on Atreca in a research report on Tuesday, April 21st. They issued an outperform rating and a $27.00 price objective for the company. Two analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of Buy and an average target price of $26.95.

NASDAQ BCEL opened at $20.66 on Wednesday. Atreca has a one year low of $9.51 and a one year high of $29.35. The company’s 50-day simple moving average is $19.58 and its two-hundred day simple moving average is $18.05.

Atreca (NASDAQ:BCEL) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.73) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.73). On average, equities research analysts expect that Atreca will post -3.07 EPS for the current year.

In related news, insider Norman Michael Greenberg sold 10,272 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $21.83, for a total value of $224,237.76. Following the sale, the insider now owns 10,272 shares in the company, valued at $224,237.76. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Tito Serafini sold 10,000 shares of the stock in a transaction that occurred on Thursday, April 16th. The stock was sold at an average price of $16.28, for a total transaction of $162,800.00. Following the completion of the transaction, the insider now owns 3,655 shares in the company, valued at approximately $59,503.40. The disclosure for this sale can be found here. Over the last three months, insiders sold 107,472 shares of company stock worth $1,953,023. 9.90% of the stock is owned by insiders.

Several institutional investors have recently modified their holdings of BCEL. Ameritas Investment Partners Inc. lifted its position in Atreca by 170.9% during the first quarter. Ameritas Investment Partners Inc. now owns 1,490 shares of the company’s stock valued at $25,000 after purchasing an additional 940 shares during the period. Legal & General Group Plc lifted its holdings in shares of Atreca by 105.7% in the 1st quarter. Legal & General Group Plc now owns 2,658 shares of the company’s stock valued at $43,000 after buying an additional 1,366 shares during the period. US Bancorp DE purchased a new stake in shares of Atreca in the first quarter worth about $46,000. Citigroup Inc. grew its holdings in Atreca by 673.0% during the fourth quarter. Citigroup Inc. now owns 3,007 shares of the company’s stock worth $47,000 after acquiring an additional 2,618 shares during the period. Finally, Exane Derivatives acquired a new stake in Atreca during the first quarter worth about $71,000. 62.14% of the stock is owned by hedge funds and other institutional investors.

Atreca Company Profile

Atreca, Inc, a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody in preclinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform.

Read More: What is the significance of the death cross?

Analyst Recommendations for Atreca (NASDAQ:BCEL)

Receive News & Ratings for Atreca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atreca and related companies with MarketBeat.com's FREE daily email newsletter.